查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2039090

神經纖維瘤藥物治療市場：依疾病、通路及地區分類

Neurofibromatosis Treatment Drugs Market, By Disease Type, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2026 年，神經纖維瘤藥物治療市場規模將達到 207.85 億美元，到 2033 年將達到 490.85 億美元。預計 2026 年至 2033 年的複合年成長率將達到 13.4%。

報告範圍 報告詳情
基準年： 2025 2026年市場規模： 207.85億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
2026年至2033年預測期間的複合年成長率： 13.40% 2033年市場規模預測： 490.85億美元

神經纖維瘤是一種遺傳性神經系統疾病，主要影響神經細胞的生長。其特徵是神經上出現腫瘤。神經纖維瘤通常被認為是一種主要影響兒童的遺傳性疾病，但它也可能由基因突變（改變）引起。神經纖維瘤腫瘤通常是良性的，但有時也會惡性轉化。神經纖維瘤分為三種：1 型（NF1）、2 型（NF2）和神經鞘瘤。這三種類型均表現出多種不同的症狀。

市場動態

預計在預測期內，製藥和生物技術公司對神經纖維瘤新型療法的研發投入將推動神經纖維瘤藥物治療市場的成長。例如，2020年7月8日，諾貝爾製藥啟動了一項III期臨床試驗，旨在評估NPC-12G凝膠長期治療1型神經纖維瘤患者的安全性和有效性。該試驗預計於2022年4月30日完成。

本次調查的主要特點

  • 本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
  • 此外，本研究還提供了有關市場促進因素、限制因素、機會、新藥上市和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的關鍵見解。
  • 本研究根據以下參數對全球神經纖維瘤藥物治療市場的主要參與者進行了分析：公司概況、財務表現、藥物組合、市場佔有率、分銷策略、主要發展、戰略和未來計劃。
  • 本次調查涵蓋的主要公司包括Astra Zeneca。
  • 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的藥物上市、藥物類別升級、市場擴張和行銷策略做出明智的決策。
  • 這份《全球神經纖維瘤藥物治療市場報告》旨在為該行業的各種相關人員提供參考，包括投資者、供應商、製藥製造商、經銷商、新參與企業和金融分析師。
  • 透過分析全球神經纖維瘤藥物治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

  • 研究目標
  • 前提
  • 簡稱

第2章 市場範圍

  • 報告摘要
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 影響分析
  • 市場機遇
  • 合作關係與收購
  • 監管趨勢

第4章：全球神經纖維瘤藥物治療市場：依疾病類型分類，2021-2033年

  • 1型神經纖維瘤（NF1）
  • 2型神經纖維瘤（NF2）
  • 神經鞘瘤病

第5章：全球神經纖維瘤藥物治療市場：依通路分類，2021-2033年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章：全球神經纖維瘤藥物治療市場：依地區分類，2021-2033年

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 中非
    • 北非

第7章 競爭情勢

  • 公司簡介
    • AstraZeneca Plc
    • SpringWorks Therapeutics
    • Novartis
    • Pfizer
    • Takeda Pharmaceutical
    • Roche
    • Healx
    • NFlection Therapeutics
    • Fosun Pharmaceutical
    • Recursion Pharmaceuticals

第8章 分析師建議

  • 機會
  • 分析師意見
  • 連貫的機會地圖

第9章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於本公司
簡介目錄
Product Code: CMI4188

Neurofibromatosis Treatment Drugs Market is estimated to be valued at USD 20,785 Mn in 2026 and is expected to reach USD 49,085 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 20,785 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 13.40% 2033 Value Projection: USD 49,085 Mn

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.

Market Dynamics

The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.

Key features of the study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key company covered as a part of this study includes AstraZeneca
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.

Neurofibromatosis Treatment Drugs Market Segmentation

  • By Disease Type (Revenue, USD Mn, 2026-2033)
    • Neurofibromatosis 1 (NF1)
    • Neurofibromatosis 2 (NF2)
    • Schwannomatosis
  • By Distribution Channel (Revenue, USD Mn, 2026-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region (Revenue, USD Mn, 2026-2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Key Players
    • AstraZeneca
    • SpringWorks Therapeutics
    • Novartis
    • Pfizer
    • Takeda Pharmaceutical
    • Roche
    • Healx
    • NFlection Therapeutics
    • Fosun Pharmaceutical
    • Recursion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Impact Analysis
  • Market Opportunities
  • Collaborations and Acquisition
  • Regulatory Scenario

4. Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2021-2033 (USD Mn)

  • Introduction
    • Market Share Analysis, 2026, and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Neurofibromatosis 1 (NF1)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Neurofibromatosis 2 (NF2)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Schwannomatosis
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

5. Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2021-2033 (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Hospital Pharmacies
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Retail Pharmacies
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Online Pharmacies
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

6. Global Neurofibromatosis Treatment Drugs Market, By Region, 2021-2033 (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2026, and 2033 (%)
    • Y-o-Y Growth Analysis, For Region, 2022 - 2033
  • North America
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
      • South Africa
      • Central Africa
      • North Africa

7. Competitive Landscape

  • Company Profiles
    • AstraZeneca Plc
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • SpringWorks Therapeutics
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Novartis
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Pfizer
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Takeda Pharmaceutical
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Roche
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Healx
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • NFlection Therapeutics
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Fosun Pharmaceutical
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Recursion Pharmaceuticals
      • Company Overview
      • Disease Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies

8. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

9. References and Research Methodology

  • References
  • Research Methodology
  • About us